journal
https://read.qxmd.com/read/38712673/safety-and-tolerability-of-amg-330-in-adults-with-relapsed-refractory-aml-a-phase-1a-dose-escalation-study
#41
JOURNAL ARTICLE
Farhad Ravandi, Marion Subklewe, Roland B Walter, Pankit Vachhani, Gert Ossenkoppele, Veit Buecklein, Hartmut Döhner, Mojca Jongen-Lavrencic, Claudia D Baldus, Lars Fransecky, Timothy S Pardee, Hagop Kantarjian, Priscilla K Yen, Lata Mukundan, Bharat Panwar, Marc R Yago, Suresh Agarwal, Sophia K Khaldoyanidi, Anthony Stein
AMG 330, a bispecific T-cell engager (BiTE®) that binds CD33 and CD3 on T cells facilitates T-cell-mediated cytotoxicity against CD33+ cells. This first-in-human, open-label, dose-escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AMG 330 in adults with relapsed/refractory acute myeloid leukemia (R/R AML). Amongst 77 patients treated with AMG 330 (0.5 µg/day-1.6 mg/day) on 14-day or 28-day cycles, maximum tolerated dose was not reached; median duration of treatment was 29 days...
May 7, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38712556/advances-in-the-management-of-higher-risk-myelodysplastic-syndromes-future-prospects
#42
REVIEW
Georgina Gener-Ricos, Juan Jose Rodriguez-Sevilla, Samuel Urrutia, Alex Bataller, Alexandre Bazinet, Guillermo Garcia-Manero
Higher-risk myelodysplastic syndromes (HR-MDS) are defined using a number of prognostic scoring systems that include the degree of cytopenias, percentage of blasts, cytogenetic alterations, and more recently genomic data. HR-MDS encompasses characteristics such as progressive cytopenias, increased bone marrow blasts, unfavorable cytogenetics, and an adverse mutational profile. Survival is generally poor, and patients require therapy to improve outcomes. Hypomethylating agents (HMAs), such as azacitidine, decitabine, and more recently, oral decitabine/cedazuridine, are the only approved therapies for HR-MDS...
May 7, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38710017/the-degree-of-hla-matching-determines-the-incidence-of-cytokine-release-syndrome-and-associated-nonrelapse-mortality-in-matched-related-and-unrelated-allogeneic-stem-cell-transplantation-with-post-transplant-cyclophosphamide
#43
JOURNAL ARTICLE
Peter A von dem Borne, Berit M Kemps-Mols, Liesbeth C de Wreede, Adriaan A van Beek, Tjeerd J F Snijders, Daniëlle van Lammeren, Janneke Tijmensen, Aniko Sijs-Szabó, Mirjam A Oudshoorn, Constantijn J M Halkes, Peter van Balen, W A Erik Marijt, Jennifer M L Tjon, Joost S P Vermaat, Hendrik Veelken
Cytokine release syndrome (CRS) occurs frequently after haplo-identical allogeneic stem cell transplantation (alloSCT) with post-transplant cyclophosphamide (PTCy), increasing nonrelapse mortality (NRM) and decreasing survival. Data on CRS in HLA-matched alloSCT are limited and effects of specific HLA-mismatches on CRS development unknown. We hypothesized that in HLA-matched alloSCT increasing degrees of HLA-mismatching influence CRS incidence, NRM and survival. Retrospective analysis of 126 HLA-matched PTCy-alloSCT patients showed that higher degrees of HLA-mismatching significantly increased CRS incidence (26%, 75% and 90% CRS with 12/12, 10/10 and 9/10 matched donors, respectively)...
May 6, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38708448/risk-factors-for-treatment-related-bone-loss-and-osteoporosis-in-patients-with-follicular-lymphoma
#44
JOURNAL ARTICLE
Yong Xing, Kaifeng Ye, Chunyuan Li, Jinyao He, Fei Dong, Yun Tian
The survival rate of non-Hodgkin lymphoma (NHL) has steadily improved. However, osteoporosis introduced by treatment is prevalent and associated with increased mortality and disability for patients with NHL. We aimed to investigate factors impacting bone mineral density (BMD) reduction and osteoporosis, and the trend of BMD after chemotherapy. Overall, 97 newly diagnosed patients with follicular lymphoma (FL) were retrospectively enrolled. CT attenuation values were measured to assess BMD levels. Although 73...
May 6, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38696747/real-world-patterns-and-sequences-of-targeted-therapy-use-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-in-the-united-states-a-longitudinal-study
#45
JOURNAL ARTICLE
Scott F Huntington, Wendy Y Cheng, Eric M Sarpong, Siyang Leng, Mohammed Z H Farooqui, Uchechukwu Samuel Agu, Maryaline Catillon, Dominique Lejeune, Nathaniel Downes, Lisa Matay, Mei Sheng Duh, Enrico De Nigris
With increasing focus on novel targeted therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), this longitudinal claims-based study evaluated real-world CLL/SLL treatment sequences, particularly sequential targeted therapy. Among patients with first-line (1 L) treatment in 2014-2017 ( N  = 2,612; median follow-up = 3 years), the most common 1 L treatment was chemoimmunotherapy (CIT; 44.6%), followed by CD20 (25.2%) and Bruton's tyrosine kinase inhibitors (BTKi; 21...
May 2, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38696743/-braf-mutation-in-myeloid-neoplasm-incidences-and-clinical-outcomes
#46
JOURNAL ARTICLE
Tareq Abuasab, Shehab Mohamed, Naveen Pemmaraju, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Farhad Ravandi, Wei Qiao, Guillermo Montalban-Bravo, Gautam Borthakur
The presence of BRAF mutation in hematological malignancies, excluding Hairy cell leukemia, and its significance as a driver mutation in myeloid neoplasms (MNs) remains largely understudied. This research aims to evaluate patient characteristics and outcomes of BRAF -mutated MNs. Among a cohort of 6667 patients, 48 (0.7%) had BRAF -mutated MNs. Notably, three patients exhibited sole BRAF mutation, providing evidence supporting the hypothesis of BRAF 's role as a driver mutation in MNs. In acute myeloid leukemia, the majority of patients had secondary acute myeloid leukemia, accompanied by poor-risk cytogenic and RAS pathway mutations...
May 2, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38676959/direct-and-indirect-costs-for-patients-with-myeloproliferative-neoplasms
#47
JOURNAL ARTICLE
Jingbo Yu, James Nelson, Taylor Marlin, Evan Braunstein, Michelle Jerry
Myeloproliferative neoplasms (MPNs) are associated with substantial healthcare resource use and productivity loss. This retrospective cohort analysis used disability leave and medical claims data to measure direct and indirect healthcare costs associated with MPNs. The analysis included 173 patients with myelofibrosis (MF), 4477 with polycythemia vera (PV), 6061 with essential thrombocythemia (ET), and matched controls ( n  = 519, n  = 13,431, and n  = 18,183, respectively). Total healthcare costs were significantly higher for cases versus controls in each cohort (mean cost difference: MF, $67,456; PV, $10,970; ET, $22,279)...
April 27, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38659230/targets-and-treatments-in-primary-cns-lymphoma
#48
REVIEW
Christina von Roemeling, Andrés J M Ferreri, Carole Soussain, Han W Tun, Christian Grommes
Primary central nervous system lymphoma (PCNSL) is a rare and highly aggressive lymphoma entirely localized in the central nervous system or vitreoretinal space. PCNSL generally initially responds to methotrexate-containing chemotherapy regimens, but progressive or relapsing disease is common, and the prognosis is poor for relapsed or refractory (R/R) patients. PCNSL is often characterized by activation of nuclear factor kappa B (NF-κB) due to mutations in the B-cell receptor (BCR) or toll-like receptor (TLR) pathways, as well as immune evasion...
April 24, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38652865/effect-of-tyrosine-kinase-inhibitors-on-male-fertility-in-patients-with-chronic-phase-chronic-myeloid-leukemia
#49
JOURNAL ARTICLE
George Nesr, Simone Claudiani, Dragana Milojkovic, Andrew Innes, Fiona Fernando, Irene Caballes, Patience Mungozi, Richard Szydlo, Silvia Lovato, Channa Jayasena, Jane Apperley
Advancements in the management of patients with chronic myeloid leukemia (CML) allowed them to achieve survival comparable with their healthy counterparts. Consequently, their care has widened with growing focus on quality of life, including parenting children. Although tyrosine kinase inhibitors (TKI) are contraindicated in pregnancy given their teratogenic effect, their effect on male fertility is less clear with contradictory results from animal studies and case reports/series. We compared the sperm analysis parameters, as the gold-standard assessment for male fertility, of 11 patients with CP- CML before and after TKI therapy...
April 23, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38652861/challenges-in-management-of-older-patients-with-chronic-myeloid-leukemia
#50
REVIEW
Jessica M Stempel, Rory M Shallis, Rong Wong, Nikolai A Podoltsev
Tyrosine kinase inhibitors (TKIs) have significantly improved the survival of patients with chronic myeloid leukemia (CML), however, older patients are often underrepresented in pivotal trials. Approximately 20% of older adults never start treatment and face significant barriers to accomplish favorable outcomes. The treatment goal is to improve survival, prevent progression, and preserve quality of life. This is achieved through optimizing TKI doses and employing discontinuation strategies to attain treatment-free remission (TFR), a goal increasingly pursued by older patients...
April 23, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38648559/cost-effectiveness-of-adding-quizartinib-to-induction-chemotherapy-for-patients-with-flt3-mutant-acute-myeloid-leukemia
#51
JOURNAL ARTICLE
Jan Philipp Bewersdorf, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
The FLT3 inhibitor quizartinib has been shown to improve overall survival when added to intensive induction chemotherapy ("7 + 3") in patients 18-75 years old with newly diagnosed AML harboring a FLT3- ITD mutation. However, the health economic implications of this approval are unknown. We evaluated the cost-effectiveness of quizartinib using a partitioned survival analysis model. One-way and probabilistic sensitivity analyses were conducted. In the base case scenario, the addition of quizartinib to 7 + 3 resulted in incremental costs of $289,932 compared with 7 + 3 alone...
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38648546/a-retrospective-cohort-study-describing-chemotherapy-induced-peripheral-neuropathy-in-non-hodgkin-lymphoma-patients-treated-with-epoch%C3%A2-%C3%A2-%C3%A2-r-does-hiv-status-matter
#52
JOURNAL ARTICLE
Gretchen A McNally, Connor M Aossey, Tracy Wiczer, Loraine T Sinnott, Mark Lustberg, Robert A Baiocchi, Maryam Lustberg
The frontline immuno-chemotherapy regimen for HIV-associated non-Hodgkin Lymphoma is dose-adjusted EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). Chemotherapy-induced peripheral neuropathy (CIPN), caused by vincristine, is a common adverse effect of EPOCH ± R, negatively impacting long-term patient outcomes. The primary objective of this study was to determine the incidence of CIPN, stratified by HIV status, in patients treated with EPOCH ± R...
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38646879/evaluation-of-safety-outcomes-with-transitioning-obinutuzumab-from-standard-rate-to-short-duration-infusion-in-patients-with-chronic-lymphocytic-leukemia
#53
JOURNAL ARTICLE
Caroline Fleck, Allison Karabinos, Allene Cook, Donald C Moore, Ryan Jacobs
No abstract text is available yet for this article.
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38646877/evaluating-targeted-therapies-in-older-patients-with-tp53-mutated-aml
#54
REVIEW
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner
Mutation of thetumor suppressor gene, TP53 ( tumor protein 53 ), occurs in up to 15% of all patients with acute myeloid leukemia (AML) and is enriched within specific clinical subsets, most notably in older adults, and including secondary AML cases arising from preceding myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), patients exposed to prior DNA-damaging, cytotoxic therapies. In all cases, these tumors have remained difficult to effectively treat with conventional therapeutic regimens. Newer approaches fortreatmentof TP53- mutated AML have shifted to interventions that maymodulate TP53 function, target downstream molecular vulnerabilities, target non-p53 dependent molecular pathways, and/or elicit immunogenic responses...
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38638066/light-chain-restricted-russell-body-oral-mucositis-an-immunohistochemical-study-and-literature-review
#55
JOURNAL ARTICLE
Luana Stefanie Silvino Gonçalves, Karina Helen Martins, Magdalena Raquel Torres Reyes, Isabella Silva Catananti, Fernando Chahud, Jorge Esquiche León
No abstract text is available yet for this article.
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38635491/management-of-relapsed-refractory-mantle-cell-lymphoma
#56
REVIEW
Musa Alzahrani, Diego Villa
In this review we summarize the current evidence describing the management of patients with relapsed/refractory MCL and outline the various novel therapeutics that have been developed over the past two decades. We also describe how overall response rates, complete response rates, duration of responses, and life expectancy have dramatically increased with the introduction of novel therapies, particularly covalent Bruton Tyrosine Kinase inhibitors (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy. The most recent emerging options for patients with progressive disease following BTKi or CAR-T, including non-covalent BTKi, antibody-drug conjugates, Bcl-2 inhibitors, and bispecific antibodies, may further improve response rates and outcomes...
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38635368/high-remission-rates-and-transition-to-allogeneic-transplant-in-older-patients-with-newly-diagnosed-flt-3-mutated-acute-myelogenous-leukemia-with-midostaurin-plus-intensive-chemotherapy
#57
JOURNAL ARTICLE
Jose Tinajero, Dat Ngo, Jianying Zhang, Ni-Chun Tsai, Ahmed Aribi, Ibrahim Aldoss, Vaibhav Agrawal, Shukaib Arslan, Idoroenyi Amanam, Hoda Pourhassan, Karamjeet Sandhu, Monzr Al-Malki, Vinod Pullarkat, Pamela Becker, Ryotaro Nakamura, Anthony Stein, Guido Marcucci, Andrew Artz, Paul Koller, Amandeep Salhotra
No abstract text is available yet for this article.
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38629176/flotetuzumab-as-a-salvage-immunotherapy-in-advanced-cd123-positive-hematological-malignancies-a-phase-1-pilot-study
#58
JOURNAL ARTICLE
Ibrahim Aldoss, Jianying Zhang, Marjorie Robbins, Joo Song, Monzr M Al Malki, Salman Otoukesh, Karamjeet Sandhu, Vaibhav Agrawal, Alex F Herrera, Leslie L Popplewell, Lucy Ghoda, Anthony Stein, Guido Marcucci, Stephen Forman, Vinod Pullarkat
CD123 "expression" is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®. We conducted a phase 1 study evaluating safety and efficacy of flotetuzumab in relapsed/refractory ALL (Cohort A) and other advanced CD123-positive hematological malignancies (excluding myeloid malignancies) (cohort B). Thirteen patients (9 in Cohort A and 4 in Cohort B) were treated at dose level 1 (500 ng/kg/day) before early closure due to discontinuation of drug development by sponsor...
April 17, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38626450/covid-19-antibody-titers-after-tixagevimab-cilgavimab-injection-in-patients-with-hematologic-diseases-a-single-center-prospective-study
#59
JOURNAL ARTICLE
Naokazu Nakamura, Hiroko Tsunemine, Ryo Ikunari, Tomomi Sakai, Nobuyoshi Arima
Knowledge of the SARS-CoV-2 antibody titers induced by tixagevimab-cilgavimab in patients with hematologic diseases remains insufficient. Here, we performed a single-center, prospective study to reveal the changes in antibody titer after administration of tixagevimab-cilgavimab in 78 patients with hematologic diseases. The median peak titer was 155.4 U/mL, and the median AUC was 46556 days·U/mL. First, we compared several characteristics between patients with low titers (peak titer ≤ 155...
April 16, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38625039/prevalence-of-geriatric-impairments-and-frailty-categorization-among-real-world-patients-with-multiple-myeloma-a-prospective-cohort-study-mfrail
#60
JOURNAL ARTICLE
Imran Haider, Darryl P Leong, Martha Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Mohammed Aljama, Alissa Visram, Tanya M Wildes, Hira Mian
There is limited knowledge regarding the prevalence of geriatric impairments and frailty among patients with multiple myeloma (MM) in a real-world setting. This study evaluated the distribution of frailty profiles among 116 patients with newly diagnosed or relapsed MM, using four common frailty scales. The proportion of patients classified as frail varied significantly, ranging from 15.5% to 56.9%, due to differences in how frailty was operationalized between each frailty measure. Functional, cognitive, and mobility impairments were common overall and irrespective of performance status...
April 16, 2024: Leukemia & Lymphoma
journal
journal
30440
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.